CSL Behring has agreed to acquire Calimmune, a developer of gene therapy treatments that is backed by an unnamed pharmaceutical firm.
Calimmune, a US-based gene therapy developer backed by an undisclosed pharmaceutical firm, is set to be acquired by biopharmaceutical firm CSL Behring for an upfront payment of $91m.
CSL Behring may pay up to an additional $325m in milestone payments over a period of approximately eight years following the transaction, which is expected to close within two weeks.
Founded in 2006, Calimmune is working on a gene therapy for sickle cell disease and β-thalassemia, inherited, chronic disorders that affect the…
